Chu JJ - Search Results

1

Contribution of Fc-dependent cell-mediated activity of a vestigial esterase-targeting antibody against H5N6 virus infection.

Zheng Z, Teo SHC, Arularasu SC, Liu Z, Mohd-Ismail NK, Mok CK, Ong CB, Chu JJ, Tan YJ. Zheng Z, et al. Among authors: chu jj. Emerg Microbes Infect. 2020 Jan 6;9(1):95-110. doi: 10.1080/22221751.2019.1708215. eCollection 2020. Emerg Microbes Infect. 2020. PMID: 31906790 Free PMC article.

2

A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.

Lam S, Nyo M, Phuektes P, Yew CW, Tan YJ, Chu JJ. Lam S, et al. Among authors: chu jj. MAbs. 2015;7(6):1178-94. doi: 10.1080/19420862.2015.1083664. Epub 2015 Aug 25. MAbs. 2015. PMID: 26305993 Free PMC article.

3

Characterization of RyDEN (C19orf66) as an Interferon-Stimulated Cellular Inhibitor against Dengue Virus Replication.

Suzuki Y, Chin WX, Han Q, Ichiyama K, Lee CH, Eyo ZW, Ebina H, Takahashi H, Takahashi C, Tan BH, Hishiki T, Ohba K, Matsuyama T, Koyanagi Y, Tan YJ, Sawasaki T, Chu JJ, Vasudevan SG, Sano K, Yamamoto N. Suzuki Y, et al. Among authors: chu jj. PLoS Pathog. 2016 Jan 6;12(1):e1005357. doi: 10.1371/journal.ppat.1005357. eCollection 2016 Jan. PLoS Pathog. 2016. PMID: 26735137 Free PMC article.

4

Current Perspective of Antiviral Strategies against COVID-19.

Ahidjo BA, Loe MWC, Ng YL, Mok CK, Chu JJH. Ahidjo BA, et al. ACS Infect Dis. 2020 Jul 10;6(7):1624-1634. doi: 10.1021/acsinfecdis.0c00236. Epub 2020 Jun 16. ACS Infect Dis. 2020. PMID: 32485102 Review.

5

Airborne SARS-CoV-2 surveillance in hospital environment using high-flowrate air samplers and its comparison to surface sampling.

Ang AX, Luhung I, Ahidjo BA, Drautz-Moses DI, Tambyah PA, Mok CK, Lau KJ, Tham SM, Chu JJH, Allen DM, Schuster SC. Ang AX, et al. Indoor Air. 2022 Jan;32(1):e12930. doi: 10.1111/ina.12930. Epub 2021 Sep 14. Indoor Air. 2022. PMID: 34519380 Free PMC article.

6

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants.

Shan S, Mok CK, Zhang S, Lan J, Li J, Yang Z, Wang R, Cheng L, Fang M, Aw ZQ, Yu J, Zhang Q, Shi X, Zhang T, Zhang Z, Wang J, Wang X, Chu JJH, Zhang L. Shan S, et al. Front Immunol. 2021 Dec 13;12:766821. doi: 10.3389/fimmu.2021.766821. eCollection 2021. Front Immunol. 2021. PMID: 34966387 Free PMC article.

7

Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.

Zakir TS, Meng T, Carmen LCP, Chu JJH, Lin RTP, Prabakaran M. Zakir TS, et al. Viruses. 2022 Jan 24;14(2):230. doi: 10.3390/v14020230. Viruses. 2022. PMID: 35215823 Free PMC article.

8

Cytopathic Effect (CPE )-Based Drug Screening Assay for SARS-CoV-2.

Ng YL, Mok CK, Chu JJH. Ng YL, et al. Methods Mol Biol. 2022;2452:379-391. doi: 10.1007/978-1-0716-2111-0_22. Methods Mol Biol. 2022. PMID: 35554918

9

Early pathogenesis profiles across SARS-CoV-2 variants in K18-hACE2 mice revealed differential triggers of lung damages.

Aw ZQ, Mok CK, Wong YH, Chen H, Mak TM, Lin RTP, Lye DC, Tan KS, Chu JJH. Aw ZQ, et al. Front Immunol. 2022 Oct 27;13:950666. doi: 10.3389/fimmu.2022.950666. eCollection 2022. Front Immunol. 2022. PMID: 36389747 Free PMC article.

10

The host-targeting compound peruvoside has a broad-spectrum antiviral activity against positive-sense RNA viruses.

Wu KX, Yogarajah T, Loe MWC, Kaur P, Lee RCH, Mok CK, Wong YH, Phuektes P, Yeo LS, Chow VTK, Tan YW, Chu JJH. Wu KX, et al. Acta Pharm Sin B. 2023 May;13(5):2039-2055. doi: 10.1016/j.apsb.2023.03.015. Epub 2023 Mar 18. Acta Pharm Sin B. 2023. PMID: 37250169 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

401 results

Search Page